FDA approves first ophthalmic clobetasol propionate product for post-operative inflammation, entering $1.3B market.
The FDA has approved Formosa Pharmaceuticals and AimMax Therapeutics' Clobetasol Propionate Ophthalmic Suspension 0.05% (APP13007) to treat post-operative inflammation and pain following ocular surgery. This is the first FDA-approved ophthalmic clobetasol propionate product and the first new steroid in over 15 years. It offers a convenient dosing regimen and enters a $1.3B market.
March 04, 2024
3 Articles